2 hours ago · China
Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

What's happening
SignalsMonitor is following this as a politics story. South China Morning Post Asia is the outlet attached so far. The reports are tied to China. The first report grouped here was at 16 Nov 2026, 05:00 UTC. The headline in use is “Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
Shares in Hong Kong-listed Akeso plunged as much as 31. 8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook.
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by South China Morning Post Asia
Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback
Reported by 1 outlet
- South China Morning Post
- South China Morning PostAkeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback